title: Prognostic value of ERCC1 and ERCC2 gene polymorphisms in patients with gastric cancer receiving platinum-based chemotherapy.
abstract: We conducted a prospective study to analyze whether ERCC1 rs11615 and rs3212986 and ERCC2 rs13181 and rs1799793 gene polymorphisms could serve as potential biomarkers for the prognosis of gastric cancer. A total of 228 patients with pathologically proven gastric cancer and receiving platinum-based chemotherapy were recruited from our hospital between October 2009 and October 2011. The ERCC1 rs11615 and rs3212986 and ERCC2 rs13181 and rs1799793 polymorphisms were genotyped using the polymerase chain reaction restriction fragment length polymorphism (PCR-RFLP) assay. Conditional logistic regression analysis revealed that patients carrying the CA and AA genotypes of ERCC1 rs3212986 polymorphism showed a poorer response to chemotherapy compared to the CC genotype (CA vs. CC: OR = 0.28, 95% CI = 0.06-0.98, P = 0.04; AA vs. CC: OR = 0.49, 95% CI = 0.06-0.98, P = 0.01). Moreover, the CA+AA genotype of ERCC1 rs3212986 polymorphism showed a significantly poorer response to chemotherapy (CA+AA vs. CC: OR = 0.49, 95% CI = 0.27-0.90). Patients with the AA genotype of ERCC1 rs3212986 polymorphism had a longer overall survival time when compared with the CC genotype (34.91 months vs. 51.19 months, log-rank P = 0.003). The AA genotype of ERCC1 rs3212986 polymorphism in gastric cancer patients was correlated with a higher risk of death from varying causes by the Cox proportional hazards model, compared to the CC genotype (HR = 6.19, 95% CI = 1.42-30.60). In conclusion, the ERCC1 rs3212986 polymorphism was found to influence the response to chemotherapy and overall survival of gastric cancer patients.
authors.affiliation: Department of Oncology, No. 303 Hospital of Chinese People's Liberation Army Nanning, China.
authors.forename: Juanmei
authors.initials: J
authors.lastname: Mo
authors.affiliation: Department of Oncology, No. 303 Hospital of Chinese People's Liberation Army Nanning, China.
authors.forename: Min
authors.initials: M
authors.lastname: Luo
authors.affiliation: Department of Oncology, No. 303 Hospital of Chinese People's Liberation Army Nanning, China.
authors.forename: Jiandong
authors.initials: J
authors.lastname: Cui
authors.affiliation: Department of Chemotherapy, Affiliated Tumor Hospital of Guangxi Medical University Nanning, China.
authors.forename: Shaozhang
authors.initials: S
authors.lastname: Zhou
mesh_terms: D000328:Adult; D000368:Aged; D000970:Antineoplastic Agents / Q000627:therapeutic use; D014408:Biomarkers, Tumor / Q000235:genetics; D004268:DNA-Binding Proteins / Q000235:genetics*; D019008:Drug Resistance, Neoplasm / Q000235:genetics*; D004720:Endonucleases / Q000235:genetics*; D005260:Female; D005838:Genotype; D006801:Humans; D053208:Kaplan-Meier Estimate; D008297:Male; D008875:Middle Aged; D017671:Platinum Compounds / Q000627:therapeutic use; D016133:Polymerase Chain Reaction; D012150:Polymorphism, Restriction Fragment Length; D020641:Polymorphism, Single Nucleotide; D011379:Prognosis; D016016:Proportional Hazards Models; D011446:Prospective Studies; D013274:Stomach Neoplasms / Q000188:drug therapy / Q000235:genetics* / Q000401:mortality*; D016896:Treatment Outcome; D051759:Xeroderma Pigmentosum Group D Protein / Q000235:genetics*
chemical_list: D000970:Antineoplastic Agents; D014408:Biomarkers, Tumor; D004268:DNA-Binding Proteins; D017671:Platinum Compounds; C071447:ERCC1 protein, human; D004720:Endonucleases; D051759:Xeroderma Pigmentosum Group D Protein; C497292:ERCC2 protein, human
keywords: ERCC1; ERCC2; gastric cancer; polymorphism; treatment outcome
references.citation: Zhonghua Fu Chan Ke Za Zhi. 2013 Nov;48(11):847-52
references.pmid: 24444563
references.citation: PLoS One. 2014;9(9):e106600
references.pmid: 25191856
references.citation: Clin Adv Hematol Oncol. 2003 Mar;1(3):162-6
references.pmid: 16224397
references.citation: Tumour Biol. 2015 Apr;36(4):3017-23
references.pmid: 25542228
references.citation: EMBO J. 2002 Apr 15;21(8):2045-53
references.pmid: 11953324
references.citation: J Cancer Res Clin Oncol. 2014 Dec;140(12):2107-17
references.pmid: 24994039
references.citation: N Engl J Med. 2006 Sep 7;355(10):983-91
references.pmid: 16957145
references.citation: J Gastroenterol. 2008;43(4):256-64
references.pmid: 18458840
references.citation: ChemMedChem. 2014 Jun;9(6):1145-9
references.pmid: 24376113
references.citation: Biochimie. 2003 Nov;85(11):1083-99
references.pmid: 14726015
references.citation: PLoS One. 2014;9(11):e111651
references.pmid: 25375151
references.citation: Genet Mol Res. 2014;13(4):10215-22
references.pmid: 25501233
references.citation: Ann Surg Oncol. 2010 Dec;17(12):3077-9
references.pmid: 20882416
references.citation: Int J Clin Exp Pathol. 2015;8(5):5563-9
references.pmid: 26191265
references.citation: Gynecol Oncol. 2015 Jan;136(1):112-20
references.pmid: 25449309
references.citation: Mol Cell. 2007 Apr 27;26(2):245-56
references.pmid: 17466626
references.citation: Cancer Res. 1994 Jul 1;54(13):3500-5
references.pmid: 8012973
references.citation: Chin J Cancer Res. 2014 Jun;26(3):323-30
references.pmid: 25035660
references.citation: Pak J Med Sci. 2014 Nov-Dec;30(6):1403-8
references.pmid: 25674147
references.citation: Int J Clin Exp Pathol. 2015;8(3):3132-7
references.pmid: 26045829
references.citation: Genet Mol Res. 2015;14(2):5804-11
references.pmid: 26125779
references.citation: Bull Cancer. 2000 Dec;87(12):881-6
references.pmid: 11174117
references.citation: Genet Mol Res. 2015;14(2):7241-7
references.pmid: 26125934
references.citation: Cancer Invest. 2015 Apr;33(4):107-13
references.pmid: 25647444
references.citation: Int J Clin Exp Pathol. 2015;8(4):4106-12
references.pmid: 26097599
references.citation: J Transl Med. 2014;12:272
references.pmid: 25253066